SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Mol Cancer Ther (2023) 22 (4): 421–434.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Melanotransferrin (MELTF, MFI2, CD228) Expression Attenuates Malignant Melanoma Progression in the A375-Luc2 Murine Metastasis Model and Human Patients

Jana Jandova
Georg T. Wondrak

Journal of Investigative Dermatology (2024)

Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

Ina Lami
Andrew J. Wiemer

Drugs in R&D (2024) 24 (2): 129.

Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents

Filippo Spriano
Chiara Tarantelli
Luciano Cascione
Eugenio Gaudio
Gaetanina Golino
Lorenzo Scalise
Maria Teresa Cacciapuoti
Emanuele Zucca
Anastasios Stathis
Patrick H. Van Berkel
Giorgio Inghirami
Francesca Zammarchi
Francesco Bertoni

British Journal of Haematology (2024)

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

Stefano Sganga
Silvia Riondino
Giovanni Maria Iannantuono
Roberto Rosenfeld
Mario Roselli
Francesco Torino

Journal of Personalized Medicine (2023) 13 (9): 1339.

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Devra Olson
Janelle Taylor
Kelsi Willis
Kelly Hensley
Sean Allred
Margo Zaval
Lauren Farr
Robert Thurman
Nishi Jain
Renee Hein
Michelle Ulrich
Scott Peterson
Anita Kulukian

Cancer Research Communications (2023) 3 (9): 1927.